EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients

Tian Chen, Mengqiu Tang, Yang Zhou, Zhepei Wang, Shiwei Li, Hongcai Wang, Yangfang Lu, Jinguo Wang, Weiyu Shen

Frontiers in Oncology · 30.06.2023 · 13

DOI: 10.3389/fonc.2023.1216852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 30.06.2023. Verfasst von Tian Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies on the prognostic factors for patients with brain oligo-metastasis treated with fractionated stereotactic radiotherapy (FSRT) usually focus on the size of metastatic tumor and radiation dose. Some inflammatory indicators have predictive value in non-small cell lung cancer (NSCLC) with brain metastasis receiving stereotactic radiotherapy. However, the prognostic value of inflammatory indicators in NSCLC patients with brain oligo-metastasis treated with FSRT, and their effect on radiotherapy dose is unknown.

Methods

A total of 95 advanced NSCLC patients with brain oligo-metastasis who had undergone FSRT treatment at Ningbo Medical Center Lihuili Hospital between January 2015 and April 2022 were enrolled into the study. Neutrophil to lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), tumor diameter and biologically effective dose (BED10) were analyzed using Chi-square test. Univariate and multivariate Cox regressions were used to identify predictors of survival.

Results

Tumor diameter (< 2 cm), BED10 (≥ 48Gy) and LMR (≥ 4) were found to be independently associated with good intracranial local control survival (i-LCS) through multivariate analysis. The median i-LCS was longer in patients with 2 independent risk factors (tumor diameter ≥ 2 and LMR < 4) administered with BED10 > 53.6Gy compared with patients administered with BED10 ≤ 53.6Gy (20.7 months vs 12.0 months, P = 0.042). LMR ≥ 4 ( P = 0.019) and positivity for driver gene mutations ( P = 0.011) were independently associated with better overall survival (OS).

Conclusions

LMR is an independent prognostic factor of i-LCS and OS in NSCLC patients with brain oligo-metastasis treated with FSRT. Patients with tumor diameter ≥ 2 and LMR < 4 should be treated with BED10 greater than 53.6Gy.

Schlagwörter

Stichwörter der Autor:innen

biologically effective dose (BED)brain oligo-metastasisfractionated stereotactic radiotherapy (FSRT)intracranial local control survival (i-LCS)lymphocyte to monocyte ratio (LMR)

Autor:innen und Institutionen

  • Department of Radiation Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
  • Department of Ningbo Institute of Innovation for Combined Medicine and Engineering, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
  • Department of Neurosurgery, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
  • Department of Neurosurgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
  • Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.

Zitieren

APA

Chen, T., Tang, M., Zhou, Y., Wang, Z., Li, S., Wang, H., Lu, Y., Wang, J., & Shen, W. (2023). Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1216852

Vancouver

Chen T, Tang M, Zhou Y, Wang Z, Li S, Wang H, et al. Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1216852

BibTeX
@article{Chen2023,
  author = {Chen, Tian and Tang, Mengqiu and Zhou, Yang and Wang, Zhepei and Li, Shiwei and Wang, Hongcai and Lu, Yangfang and Wang, Jinguo and Shen, Weiyu},
  title = {Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1216852}
}
Kostenlos starten →